Title | Chemokines form nanoparticles with DNA and can superinduce TLR-driven immune inflammation. |
Publication Type | Journal Article |
Year of Publication | 2022 |
Authors | Du Y, Kioon MDominique, Laurent P, Chaudhary V, Pierides M, Yang C, Oliver D, Ivashkiv LB, Barrat FJ |
Journal | J Exp Med |
Volume | 219 |
Issue | 7 |
Date Published | 2022 Jul 04 |
ISSN | 1540-9538 |
Keywords | Animals, Chemokines, Dendritic Cells, DNA, Inflammation, Mice, Nanoparticles, Toll-Like Receptors |
Abstract | Chemokines control the migratory patterns and positioning of immune cells to organize immune responses to pathogens. However, many chemokines have been associated with systemic autoimmune diseases that have chronic IFN signatures. We report that a series of chemokines, including CXCL4, CXCL10, CXCL12, and CCL5, can superinduce type I IFN (IFN-I) by TLR9-activated plasmacytoid DCs (pDCs), independently of their respective known chemokine receptors. Mechanistically, we show that chemokines such as CXCL4 mediate transcriptional and epigenetic changes in pDCs, mostly targeted to the IFN-I pathways. We describe that chemokines physically interact with DNA to form nanoparticles that promote clathrin-mediated cellular uptake and delivery of DNA in the early endosomes of pDCs. Using two separate mouse models of skin inflammation, we observed the presence of CXCL4 associated with DNA in vivo. These data reveal a noncanonical role for chemokines to serve as nucleic acid delivery vectors to modulate TLR signaling, with implications for the chronic presence of IFN-I by pDCs in autoimmune diseases. |
DOI | 10.1084/jem.20212142 |
Alternate Journal | J Exp Med |
PubMed ID | 35640018 |
PubMed Central ID | PMC9161158 |
Grant List | R01 AI132447 / AI / NIAID NIH HHS / United States / / Tow Foundation / R01 AI046712 / AI / NIAID NIH HHS / United States 1R01AI132447 / NH / NIH HHS / United States / / Scleroderma Research Foundation / / / National Scleroderma Foundation / R01 AR050401 / AR / NIAMS NIH HHS / United States |
Submitted by ljc4002 on September 10, 2025 - 2:14pm